RPAM
MYOK

Rhenman & Partners Asset Management’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-190,000
Closed -$25.9M – 94
2020
Q3 		$25.9M Buy
190,000
+30,000
+19% +$3.19M 2.3% 7
2020
Q2 		$15.5M Sell
160,000
-20,000
-11% -$1.67M 1.67% 21
2020
Q1 		$8.44M Sell
180,000
-30,000
-14% -$1.92M 1.18% 38
2019
Q4 		$15.3M Buy
210,000
+10,000
+5% +$607K 1.68% 18
2019
Q3 		$10.4M Sell
200,000
-25,024
-11% -$1.33M 1.31% 31
2019
Q2 		$11.3M Hold
225,024
– – 1.24% 34
2019
Q1 		$11.7M Buy
225,024
+35,702
+19% +$1.64M 1.37% 28
2018
Q4 		$9.25M Buy
189,322
+1,050
+0.6% +$57.8K 1.06% 44
2018
Q3 		$12.3M Sell
188,272
-10,000
-5% -$588K 1.23% 39
2018
Q2 		$9.84M Buy
198,272
+30,000
+18% +$1.45M 1.01% 48
2018
Q1 		$8.21M Sell
168,272
-10,000
-6% -$520K 1.01% 43
2017
Q4 		$7.5M Buy
178,272
+27,400
+18% +$1.06M 1.01% 40
2017
Q3 		$6.46M Buy
+150,872
New +$4.81M 0.83% 50

Rhenman & Partners Asset Management's MYOK Position: Q4 2020 in Review

Rhenman & Partners Asset Management sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 190,000 shares — an estimated $25.9M sold.

Rhenman & Partners Asset Management first reported a position in MYOK in Q3 2017 and held it in 13 quarters. The position peaked at $25.9M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.

  • Rhenman & Partners Asset Management reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 190,000 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $25.9M.
  • Rhenman & Partners Asset Management first reported a position in MyoKardia, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Rhenman & Partners Asset Management's MyoKardia, Inc. Common Stock position peaked at $25.9M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.